Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q1 2024 call → NOWe need to determine if management explains the company's business direction by narrating what its counterparties are doing and scaling. The question asks if a substantial part of the forward account consists of reporting on the growth, expansion, ramp, adoption, or program build-out of specific customers, partners, etc., that the company already supplies or serves, such that the company's own coming volume is a consequence of those parties' trajectories. In the transcript, management discusses various initiatives: new stores, .com growth, loyalty program, same-day delivery with DoorDash, new brands, etc. They talk about their own actions. They mention partnerships with DoorDash for same-day delivery, but that's a service they are adding, not a counterparty scaling. They talk about new brands like Birkenstock, NordicTrack, etc., but those are suppliers, not customers. They talk about their own store openings, their own marketing, their own promotions. They mention customer behavior but not specific counterparties' trajectories. They do not describe a situation where they are supplying a specific customer or partner that is scaling up and driving their volume. The closest is DoorDash, but that's a new service they are launching, not a counterparty's expansion that they are already embedded in. They also mention their credit card and loyalty program, but those are their own. Thus, the answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.